The U.S. Food and Drug Administration has intensified scrutiny of telehealth companies marketing compounded versions of glucagon-like peptide-1 (GLP-1) receptor agonists, and a pattern emerging from enforcement actions suggests that the regulatory net may extend well beyond the companies initially warned. An analysis of publicly available affiliations reveals that the prescribing infrastructure undergirding much of the compounded weight-loss drug market is concentrated within a surprisingly small number of nationwide medical groups, raising questions about accountability, clinical oversight, and the structural relationships that regulators may next choose to examine.

Over the past six months, the FDA has issued formal warnings to more than 70 telehealth companies for marketing practices that misrepresent compounded semaglutide and tirzepatide products as FDA-approved, or that falsely imply those companies directly manufacture the formulations. Neither claim is supportable. Compounded versions of these agents have not undergone the agency’s standard approval process and have not been evaluated for safety or efficacy through the pathways governing brand-name products such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

The structural complexity of the telehealth model, however, means that the companies receiving FDA warnings do not themselves prescribe the medications. Prescribing authority rests with clinicians operating within affiliated medical groups, entities that have, until recently, attracted comparatively little regulatory attention. An analysis of the warned companies’ publicly stated affiliations identified that at least 30% of those firms maintain documented relationships with just four nationwide medical groups: Beluga Health, OpenLoop, MD Integrations, and Telegra. That concentration is notable. It suggests that a relatively small number of affiliated prescribing organizations may account for a substantial share of the compounded GLP-1 prescriptions flowing through the telehealth channel.

The implications for regulatory oversight are considerable. If enforcement actions to date have focused on the marketing and commercial presentation layer of the telehealth ecosystem, the prescribing layer, populated by these affiliated medical groups, represents a distinct and as yet less examined axis of potential liability. The FDA’s authority over drug marketing differs from its authority over the practice of medicine, which falls primarily under state medical board jurisdiction. Nevertheless, the agency retains tools to address the compounding supply chain and the representations made to patients about the products they receive.

The commercial stakes underlying this enforcement activity are substantial. Eli Lilly, which manufactures tirzepatide, has pursued an aggressive legal and regulatory strategy against compounding pharmacies producing copies of its products. With semaglutide recently removed from the FDA’s drug shortage list, and tirzepatide’s shortage designation similarly resolved, the legal basis for compounding these specific molecules under federal rules has narrowed considerably. Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act permit compounding under defined conditions, including drug shortage status, and the resolution of those shortages has shifted the compliance calculus for pharmacies and the telehealth companies they supply.

For clinicians in Hawaii and across the Pacific region who have observed patients obtaining compounded GLP-1 agents through telehealth platforms, the evolving regulatory environment warrants attention. Patients presenting with these products may have received care through one of the affiliated medical groups identified in the analysis, though the layered corporate and clinical structures involved can make that determination difficult. The question of whether patients are receiving adequate informed consent regarding the unapproved status of these formulations, and whether the prescribing encounter meets the standard expected for a controlled clinical interaction, has not been systematically evaluated in published literature.

The clinical validation gap is meaningful. Brand-name semaglutide and tirzepatide carry extensive Phase III trial data supporting their efficacy and safety profiles in obesity and type 2 diabetes management. The compounded versions share the same active molecular entity in most cases, but manufacturing quality, excipient composition, and dosing accuracy in compounded products are subject to variability that FDA-approved products are not. The agency has documented cases in which compounded GLP-1 formulations were associated with dosing errors, in part because some preparations were labeled in units inconsistent with standard clinical practice. Published adverse event reports, while limited in scope, have described cases of nausea, vomiting, and hypoglycemia associated with compounded versions, though systematic comparative safety data between compounded and approved formulations remain unavailable.

On a separate regulatory front, federal vaccine policy continues to generate uncertainty for practicing clinicians. A key advisory panel operating under the U.S. Department of Health and Human Services (HHS) has retreated from an effort to withdraw positive recommendations for coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccines. Under HHS Secretary Robert F. Kennedy Jr., some advisers had sought to halt recommendations for mRNA-based COVID-19 vaccines entirely. That effort has not advanced.

The Advisory Committee on Immunization Practices (ACIP), which advises the Centers for Disease Control and Prevention (CDC) on vaccination schedules, is scheduled to convene in the coming week. The agenda is expected to include deliberations on which vaccines Americans should receive and under what circumstances. The committee’s prior action, taken in September 2025, replaced the broad standing recommendation for COVID-19 vaccination with a shared decision-making framework, a model that places greater emphasis on individual clinician-patient discussion and de-emphasizes population-level guidance.

The shift to a shared decision-making model carries implementation consequences that are not uniformly appreciated outside clinical settings. For practices serving Hawaii’s diverse patient population, including communities with varying levels of health literacy, access to primary care, and historical experience with institutional medicine, a framework that depends on nuanced patient-clinician dialogue introduces equity considerations that a uniform recommendation does not. Shared decision-making is a well-established and appropriate model for interventions where individual risk-benefit profiles vary considerably. Its application to a widely available, extensively studied vaccine raises distinct questions about the communicative infrastructure required to implement it equitably at scale.

The HHS decision in August 2025 to wind down mRNA vaccine development activities within its biomedical research division adds a longer-term dimension to this policy trajectory. The mRNA platform demonstrated considerable adaptability during the COVID-19 pandemic and had been under active investigation for applications in influenza, respiratory syncytial virus (RSV), and oncology. The contraction of federal support for this research direction affects not only near-term vaccine pipeline activity but also the institutional knowledge base and manufacturing capacity that would be required to respond to a future novel pathogen. The clinical and public health research community has noted this concern in published commentary, though the policy direction has not changed.

For Hawaii clinicians, these converging developments, one in pharmaceutical regulation and one in vaccine policy, share a common thread: both involve regulatory and advisory bodies navigating terrain in which the evidentiary foundation is stronger than the policy coherence. Compounded GLP-1 drugs lack the validation infrastructure of their approved counterparts, yet demand has driven a market that regulators are now working to constrain after the fact. mRNA COVID-19 vaccines carry a substantial body of safety and efficacy data accumulated across multiple seasons and billions of doses administered globally, yet advisory structures have moved toward more restrictive and individually contingent guidance.

Clinicians advising patients on weight management who inquire about compounded semaglutide or tirzepatide should be prepared to explain the regulatory status of these products clearly, including that the formulations are not FDA-approved, that quality control standards may differ from those governing approved products, and that the telehealth encounter through which a prescription was obtained may involve a prescribing structure several steps removed from a direct clinical relationship. Patients who have obtained these products and present with adverse effects should be encouraged to report through MedWatch, the FDA’s voluntary reporting system.

Those advising patients on COVID-19 vaccination should note that, notwithstanding advisory committee proceedings, the clinical evidence supporting vaccination in eligible adults has not changed. Guidance from professional societies, including the American College of Physicians and the Infectious Diseases Society of America, continues to support vaccination. The practical implication of the shared decision-making framework is that clinicians bear greater individual responsibility for initiating these discussions proactively, rather than relying on a standing population-level recommendation to prompt patient inquiry.

The regulatory and advisory developments described here are ongoing. The FDA’s enforcement posture toward compounded GLP-1 products and their associated telehealth and prescribing networks will likely continue to evolve as shortage designations remain resolved and the agency works through its review of individual compounding pharmacy applications for tirzepatide. The ACIP meeting scheduled for next week may provide additional clarity on the committee’s direction for the 2026 vaccine schedule. Both areas merit continued monitoring by physicians, clinical administrators, and public health professionals throughout the state.